Dark

Check out our Dark Pool Levels

LUCD
Lucid Diagnostics Inc. Common Stock
stock NASDAQ

At Close

Jul 16, 2026 3:59:58 PM EDT

1.02USD-11.304%(-0.13)2,679,307

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 16, 2026 9:25:30 AM EDT

1.12USD-2.609%(-0.03)68,705

After-hours

Jul 16, 2026 4:41:30 PM EDT

1.02USD0.000%(0.00)600

Overview HistoricalExchangesShortsNews

Dec 27, 2021

10:12AM EST Analyst Ratings For Lucid Diagnostics Benzinga

06:22AM EST Ascendiant Capital Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $16 Benzinga

Dec 15, 2021

06:37AM EST Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $13 Benzinga

Dec 1, 2021

08:34AM EST Lucid Diagnostics, PAVmed Majority-Owned Subsidiary Highlight Launch Of Its EsoGuard Telemedicine Program In Partnership With Telemedicine Co. UpScriptHealth, No Terms Disclosed Benzinga

Nov 18, 2021

08:06AM EST CORRECTION: Lucid Diagnostics Ticker Is 'LUCD' Benzinga

Nov 16, 2021

04:15PM EST PAVmed, Lucid Diagnostics See Q3 2021 EsoGuard Related Revenue 200K; Sees GAAP EPS $(0.15) Benzinga

Nov 11, 2021

08:39AM EST PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers Benzinga

Nov 8, 2021

11:06AM EST BTIG Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $14 Benzinga

10:37AM EST UPDATE: Needham On Lucid Buy Initiation: Firm Sees EsoGuard & Sample Collection System EsoCheck Presenting An 'Unmet Need With A Very Large Total Available Market' Of $25B In The U.S. Alone; Notes Long-Term Plans To Expand Into Treatment Using EsoCure Benzinga

10:18AM EST Canaccord Genuity Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $18 Benzinga

09:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 Benzinga

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

06:14AM EST Cantor Fitzgerald Initiates Coverage On Lucid Diagnostics with Overweight Rating, Announces Price Target of $21 Benzinga

05:16AM EST Needham Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $17 Benzinga

Oct 21, 2021

12:11PM EDT 3 Stocks Insiders Are Buying Benzinga

Oct 18, 2021

05:45PM EDT Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering GlobeNewswire Inc

05:23PM EDT PAVmed 8-K Shows Co. Purchased ~571K Shares In IPO Of Its Majority-Owned Subsidiary, Lucid Diagnostics Benzinga

Oct 14, 2021

11:04AM EDT Lucid Diagnostics Shares Open For Trade At $12.75; IPO Priced $14/Share Benzinga

09:22AM EDT Lucid Diagnostics Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced $14/Share Benzinga

08:07AM EDT The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts Benzinga

Oct 13, 2021

10:15PM EDT Lucid Diagnostics Announces Pricing of Initial Public Offering GlobeNewswire Inc

Share